UniXell Biotechnology Announces the First Patient Dosed with UX-DA001, an Investigational Autologous iPSC Based Cell Therapy for the Treatment of Parkinson’s Disease, in Its Phase I Study
Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech) announced the successful first administration of its proprietary Parkinson’s disease cell drug UX-DA001 in China.